Trial Profile
A Phase 1 Study of MONALIZUMAB (IPH2201), a Humanized Anti CD94/NKG2A Monoclonal Antibody (Mab) Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (SCT) Prepared With a Reduced Intensity Conditioning
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2022
Price :
$35
*
At a glance
- Drugs Monalizumab (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Haematological malignancies; Lymphoma; Myelodysplastic syndromes; Myelofibrosis
- Focus Adverse reactions
- Acronyms PIRAT
- 14 Dec 2021 Status changed from recruiting to completed, as per results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 18 Sep 2018 Planned End Date changed from 1 Apr 2019 to 28 Apr 2020.